Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retractable TechnologiesRVP 35 EV-to-EBITDA is -9.06 as of Jul. 29, 2026. GuruFocus rates RVP with a GF Score™ of 35/100 and a GF Value™ of $0.76 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Retractable Technologies ranks better than 99.8% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Retractable Technologies's enterprise value is $-14.42 Mil.
Retractable Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1.59 Mil. Therefore, Retractable Technologies's EV-to-EBITDA for today is -9.06.
The historical rank and industry rank for Retractable Technologies's EV-to-EBITDA or its related term are showing as below:
RVP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -94.08 Med: 1.35 Max: 60.25
Current: -9.06
During the past 13 years, the highest EV-to-EBITDA of Retractable Technologies was 60.25. The lowest was -94.08. And the median was 1.35.
RVP's EV-to-EBITDA is ranked better than 99.8% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.25
vs RVP: -9.06
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Retractable Technologies's PE Ratio (TTM) for today is calculated as:
Retractable Technologies's share price for today is $0.6701.
Retractable Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Retractable Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Retractable Technologies EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Retractable Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Retractable Technologies's EV-to-EBITDA falls into.
Retractable Technologies's current Enterprise Value is $-14.42 Mil.
Retractable Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.59 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retractable Technologies (RVP) has a EV-to-EBITDA of -9.06 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Retractable Technologies. According to the industry distribution chart, Retractable Technologies ranks #1 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 0.2%.
Is Retractable Technologies' EV-to-EBITDA too high?
Retractable Technologies' current EV-to-EBITDA is -9.06. Based on the distribution chart, Retractable Technologies ranks #1 out of 512 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Retractable Technologies has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Retractable Technologies' EV-to-EBITDA compare to ZJYL and RGNT?
According to the Medical Devices & Instruments industry distribution chart, Retractable Technologies ranks #1 out of 512 companies for EV-to-EBITDA. This places Retractable Technologies in the top 0% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.25, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Retractable Technologies. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Retractable Technologies's current EV-to-EBITDA is -9.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Retractable Technologies stock overvalued right now?
Based on GuruFocus' analysis, Retractable Technologies (RVP) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.76, compared to a current price of $0.67 — trading 11.8% below its estimated fair value. The current EV-to-EBITDA is -9.06. Retractable Technologies' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Retractable Technologies (RVP), the current EV-to-EBITDA is -9.06 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Retractable Technologies (RVP) Overvalued in 2026?
Based on GuruFocus' analysis, Retractable Technologies stock appears to be undervalued.
The current stock price of $0.67 is trading 11.8% below its estimated GF Value™ of $0.76.
GuruFocus considers Retractable Technologies to be Modestly Undervalued.
Key valuation signals for RVP:
EV-to-EBITDA: -9.06
GF Value™: $0.76 vs. price of $0.67 (11.8% below fair value)
No single metric tells the full story. See the RVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Retractable Technologies Inc is engaged in the manufacturing and marketing of safety medical products (predominantly syringes) for the healthcare industry. It has manufacturing facilities in Little Elm, Texas, and uses manufacturers in China as well. Its syringes are well-suited for administering vaccinations. The company's products are VanishPoint Syringe, VanishPoint Insulin Syringes, EasyPoint Needle, EasyPoint Blood Collection Tube with Needle, VanishPoint Blood Collection Set, and VanishPoint IV Catheter. It provides solutions such as Insulin, Immunization, Blood Collection, Allergy, General Purpose, and Infusion.
35GF Score
Get the complete analysis for RVP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVP has been successfully added to your 
